RATIONALE: The lack of potent, selective, brain penetrant Y(2) receptor antagonists has hampered in vivo functional studies of this receptor. OBJECTIVE: Here, we report the in vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y(2) receptor antagonist. METHODS: The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y(2) receptors in KAN-Ts cells and rat Y(2) receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y(2) bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release. RESULTS: JNJ-31020028 bound with high affinity (pIC(50) = 8.07 +/- 0.05, human, and pIC(50) = 8.22 +/- 0.06, rat) and was >100-fold selective versus human Y(1), Y(4), and Y(5) receptors. JNJ-31020028 was demonstrated to be an antagonist (pK(B) = 8.04 +/- 0.13) in functional assays. JNJ-31020028 occupied Y(2) receptor binding sites (approximately 90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake. CONCLUSION: These results suggest that Y(2) receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.
RATIONALE: The lack of potent, selective, brain penetrant Y(2) receptor antagonists has hampered in vivo functional studies of this receptor. OBJECTIVE: Here, we report the in vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y(2) receptor antagonist. METHODS: The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y(2) receptors in KAN-Ts cells and rat Y(2) receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y(2) bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release. RESULTS:JNJ-31020028 bound with high affinity (pIC(50) = 8.07 +/- 0.05, human, and pIC(50) = 8.22 +/- 0.06, rat) and was >100-fold selective versus human Y(1), Y(4), and Y(5) receptors. JNJ-31020028 was demonstrated to be an antagonist (pK(B) = 8.04 +/- 0.13) in functional assays. JNJ-31020028 occupied Y(2) receptor binding sites (approximately 90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake. CONCLUSION: These results suggest that Y(2) receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.
Authors: Ngozi Erondu; Ira Gantz; Bret Musser; Shailaja Suryawanshi; Madhuja Mallick; Carol Addy; Josee Cote; George Bray; Ken Fujioka; Harold Bays; Priscilla Hollander; Sandra M Sanabria-Bohórquez; WaiSi Eng; Bengt Långström; Richard J Hargreaves; H Donald Burns; Akio Kanatani; Takehiro Fukami; Douglas J MacNeil; Keith M Gottesdiener; John M Amatruda; Keith D Kaufman; Steven B Heymsfield Journal: Cell Metab Date: 2006-10 Impact factor: 27.287
Authors: Fabrizio Bacchi; Aleksander A Mathé; Patricia Jiménez; Luigi Stasi; Roberto Arban; Philip Gerrard; Laura Caberlotto Journal: Peptides Date: 2006-09-07 Impact factor: 3.750
Authors: E Painsipp; T Wultsch; M E Edelsbrunner; R O Tasan; N Singewald; H Herzog; P Holzer Journal: Genes Brain Behav Date: 2008-07 Impact factor: 3.449
Authors: K L Seldeen; P G Halley; C H Volmar; M A Rodríguez; M Hernandez; M Pang; S K Carlsson; L J Suva; C Wahlestedt; B R Troen; S P Brothers Journal: Neuropeptides Date: 2017-11-07 Impact factor: 3.286
Authors: Marsida Kallupi; Leandro F Vendruscolo; Casey Y Carmichael; Olivier George; George F Koob; Nicholas W Gilpin Journal: Addict Biol Date: 2013-05-03 Impact factor: 4.280
Authors: Lisa R Beutler; Yiming Chen; Jamie S Ahn; Yen-Chu Lin; Rachel A Essner; Zachary A Knight Journal: Neuron Date: 2017-10-11 Impact factor: 17.173